NCT01299571

AVODART(Dutasteride) Post-marketing Surveillance(PMS)

An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVODART(Dutasteride) Administered in Korean BPH(Benign Prostatic Hyperplasia) Patients According to the Prescribing Information

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,977 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of AVODART administered in Korean BPH patients according to the prescribing information

Conditions

• Benign Prostatic Hyperplasia
• Prostatic Hyperplasia

Interventions

Type	Name	Description
DRUG	Dutasteride	Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Timeline

• Start date: 2004-12-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2011-02-18
• Last updated: 2017-07-05
• Results posted: 2011-04-18

Locations

1 site across 1 country: South Korea